In this webinar, Ramji Srinivasan, CEO and Cofounder, analyzes three published spectral flow reports and runs a hypothetical eight-marker panel against them. He compares the differences between the outputs of each panel.
Watch to answer the underlying questions, “What do developers find from high-resolution cytometry? Is any of it even useful?”
Papers Covered:
Edwards JM, Andrews MC, Burridge H, Smith R, Owens C, Edinger M, Pilkington K, Desfrancois J, Shackleton M, Senthi S, van Zelm MC. Design, optimisation and standardisation of a high-dimensional spectral flow cytometry workflow assessing T-cell immunophenotype in patients with melanoma. Clin Transl Immunology. 2023 Sep 7;12(9):e1466. doi: 10.1002/cti2.1466. PMID: 37692904; PMCID: PMC10484688.
Mahalingam, D., Chen, S., Xie, P. et al. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). Br J Cancer 129, 782–790 (2023). https://doi.org/10.1038/s41416-023-02344-5
Dorff, T.B., Blanchard, M.S., Adkins, L.N. et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 30, 1636–1644 (2024). https://doi.org/10.1038/s41591-024-02979-8
Before Teiko, Ramji was Cofounder, CEO and Chairman of Counsyl, a women’s health genetic screening laboratory. Counsyl screened over 1M prospective parents, mothers-to-be and women at risk of hereditary cancer. In 2018, Counsyl was acquired by Myriad Genetics, Inc for $375M in cash and stock.
Ramji earned a B.S. in computer science and an M.S. in financial mathematics, both from Stanford University. Ramji also attended Stanford’s Graduate School of Business before dropping out to start Counsyl.
